Title:
ＣＤＫ阻害剤としての４－［［（７－アミノピラゾロ［１，５－ａ］ピリミジン－５－イル）アミノ］メチル］ピペリジン－３－オール化合物
Document Type and Number:
Japanese Patent JP7148604
Kind Code:
B2
Abstract:
The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds (referred to herein as “APPAMP compounds”) that, inter alia, inhibit (e.g., selectively inhibit) CDK (e.g., CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, CDK13, etc.). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CDK; and to treat disorders including: disorders that are associated with CDK; disorders that result from an inappropriate activity of a cyclin-dependent kinase (CDK); disorders that are associated with CDK mutation; disorders that are associated with CDK overexpression; disorders that are associated with upstream pathway activation of CDK; disorders that are ameliorated by the inhibition of CDK; proliferative disorders; cancer; viral infections (including HIV); neurodegenerative disorders (including Alzheimer's disease and Parkinson's disease); ischaemia; renal diseases; cardiovascular disorders (including atherosclerosis); and autoimmune disorders (including rheumatoid arthritis). Optionally, the treatment further comprises treatment (e.g., simultaneous or sequential treatment) with a further active agent which is, e.g., an aromatase inhibitor, an anti-estrogen, a Her2 blocker, a cytotoxic chemotherapeutic agent, etc.
More Like This:
| WO/2014/087208 | A PROCESS OF PREPARING ALCAFTADINE |
| JP5006606 | Compounds for organic EL devices and organic EL devices |
| JPH09288365 | ELECTROPHOTOGRAPHIC PHOTORECEPTOR |
Inventors:
Bar, ash
Einskow, Ed
Bonke, Alexander
Barrett, Anthony, GM.
Snose, Mihiro
Shields, Jason John
Chohan, Kamal Deep
Einskow, Ed
Bonke, Alexander
Barrett, Anthony, GM.
Snose, Mihiro
Shields, Jason John
Chohan, Kamal Deep
Application Number:
JP2020517114A
Publication Date:
October 05, 2022
Filing Date:
September 20, 2018
Export Citation:
Assignee:
Karik Therapeutics Limited
CANCER RESEARCH TECHNOLOGY LIMITED
IP2 IPO Innovations Limited
CANCER RESEARCH TECHNOLOGY LIMITED
IP2 IPO Innovations Limited
International Classes:
C07D487/04; A61K31/138; A61K31/282; A61K31/337; A61K31/4196; A61K31/513; A61K31/517; A61K31/519; A61K31/565; A61K31/5685; A61K31/675; A61K31/704; A61K31/7068; A61K39/395; A61K45/00; A61P9/00; A61P9/10; A61P13/12; A61P17/06; A61P19/02; A61P25/16; A61P25/28; A61P29/00; A61P31/12; A61P35/00; A61P37/06; A61P43/00
Domestic Patent References:
| JP2017506250A | ||||
| JP2010529140A |
Other References:
PARUCH, Kamil et al.,Bioorg. Med. Chem. Lett.,2007年,17,6220-6223
HAZEL, Pascale et al.,ChemMedChem,2017年,12,372-380
HAZEL, Pascale et al.,ChemMedChem,2017年,12,372-380
Attorney, Agent or Firm:
Hiraki International Patent Office
Previous Patent: Controller and motor assembly including this
Next Patent: Semaglutide in medical therapy
Next Patent: Semaglutide in medical therapy